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Abstract
Background: The aim of the present study was to investigate microglia activation over time following traumatic
brain injury (TBI) and to relate these findings to glutamate release.
Procedures: Sequential dynamic (R)-[11C]PK11195 PET scans were performed in rats 24 hours before (baseline), and
one and ten days after TBI using controlled cortical impact, or a sham procedure. Extracellular fluid (ECF) glutamate
concentrations were measured using cerebral microdialysis. Brains were processed for histopathology and
(immuno)-histochemistry.
Results: Ten days after TBI, (R)-[11C]PK11195 binding was significantly increased in TBI rats compared with both
baseline values and sham controls (p < 0.05). ECF glutamate values were increased immediately after TBI (27.6 ±
14.0 μmol·L-1) as compared with the sham procedure (6.4 ± 3.6 μmol·L-1). Significant differences were found
between TBI and sham for ED-1, OX-6, GFAP, Perl’s, and Fluoro-Jade B.
Conclusions: Increased cerebral uptake of (R)-[11C]PK11195 ten days after TBI points to prolonged and ongoing
activation of microglia. This activation followed a significant acute posttraumatic increase in ECF glutamate levels.
Background
Microglia are immunocompetent brain cells, expressing
a variety of cytokine, chemokine, and neurotransmitter
receptors, including receptors for glutamate, the princi-
ple excitatory amino acid (EAA) in the central nervous
system (CNS), when activated [1]. In the neuroinflam-
matory cascade that follows traumatic brain injury
(TBI), activated microglia may play a crucial role in the
aetiology and progression of excito-neurotoxic brain
lesions. Excito-neurotoxicity after TBI mainly results
from excessive glutamate release with subsequent exces-
sive influx of Ca2+, primarily mediated by N-methyl D-
aspartate (NMDA) glutamate receptors [2]. Glutamate
release induces excitotoxicity and contributes to the
pathophysiology of numerous neurological diseases
including ischemia, inflammation, epilepsy, and
neurodegenerative diseases [3,4]. In TBI, glutamate is
released in large quantities into the extracellular fluid
(ECF) by neurons and glial cells. However, in the post-
traumatic neuroinflammatory cascade the relation
between initial glutamate release and time course of
microglia activation is not yet clear.
In vivo, activated microglia can be quantified using
(R)-[11C]PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-
methyl-propyl]-3-isoquinoline carboxamide) and posi-
tron emission tomography (PET) [5,6]. In CNS diseases,
transition of microglia from a normal resting state into
a pathologically activated state has been associated with
a marked increase in expression of the 18 kDa translo-
cator protein (TSPO), previously known as the periph-
eral-type benzodiazepine receptor [7,8]. (R)-[11C]
PK11195 is a highly selective ligand for TSPO, which
can be used to monitor distribution and time course of
microglia activation following TBI [5].
The purpose of the present study was to investigate
the feasibility of determining microglia activation over
* Correspondence: h.folkersma@amc.nl
1Neurosurgical Center Amsterdam, VU University Medical Center, De
Boelelaan 1117, NL-1081 HV Amsterdam, the Netherlands
Full list of author information is available at the end of the article




© 2011 Folkersma et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
time following traumatic brain injury (TBI), to deter-
mine such activation, and to relate these findings to glu-
tamate release. To this end, in vivo cerebral
microdialysis after TBI or sham was combined with
sequential (R)-[11C]PK11195 brain PET scans and
autopsy.
Methods
Controlled cortical impact injury (CCI)
Wistar rats (male, body weight around 300 g, Harlan,
The Netherlands) were either subjected to focal TBI (n
= 6) or a sham procedure (n = 6). Anaesthetic proce-
dures and surgical preparation for CCI have been
described previously [9]. In short, rats were anaesthe-
tized in a ventilated anaesthesia chamber. After endotra-
cheal intubation with a 16-gauge Teflon catheter, rats
were mechanically ventilated at a respiratory rate of 80
breaths per minute and remained under full anaesthesia
during the whole experiment (Isofluran 1-2%, oxygen
0.45 volume %). The iliac artery was cannulated with a
14G polymer catheter (length 25 mm) and connected to
a pressure transducer to monitor blood pressure and
obtain blood gases. Vital signs were monitored continu-
ously and level of anaesthesia was evaluated by monitor-
ing the pinch reflex. Body temperature of the animals
was kept within normal range (37 -38 °C) using cooling
and heating pads. Animals were placed in a stereotactic
frame, and a craniotomy was performed over the right
parietal cortex between lambda and bregma and
approximately 2 mm lateral to the central suture. A
rounded impactor tip with a diameter of 7 mm was
adjusted to produce an impact at the centre of the
exposed brain with an impact velocity of 5 m·s-1, dura-
tion of 130 ms, and an impact depth of 3 mm. Sham-
operated rats underwent identical surgical procedures,
except for the CCI.
(R)-[11C]PK11195 PET
(R)-[11C]PK11195 was synthesized according to the
method described by Shah et al [10]. This procedure
resulted in a GMP compliant, pyrogen-free, sterile batch
of (R)-[11C]PK11195 with radiochemical purity of > 98%
and mean specific activity of 100 ± 36 GBq·μmol-1. Rats
were anaesthetized with Isofluran 5% in a ventilated
anaesthesia chamber, before breathing through a ventila-
tion mask (Isofluran 1-2%, oxygen 0.45 volume %) dur-
ing scanning. (R)-[11C]PK11195 was administered via a
jugular vein cannula. In all rats (R)-[11C]PK11195 brain
scans were performed 24 hours before intervention
(baseline), and at one and ten days after TBI.
PET studies were performed using a single lutetium
oxy-orthosilicate (LSO) crystal layer High Resolution
Research Tomograph (HRRT, CTI/Siemens, Knoxville,
TN, USA). The spatial resolution of this scanner is
approximately 2.5 mm in all directions, and the absolute
point-source sensitivity is as high as 7%. Performance
characteristics of this scanner have been reported pre-
viously [11]. The combination of high spatial resolution
and high sensitivity makes the HRRT an ideal PET scan-
ner for dynamic studies in small laboratory animals
[12,13].
First, a transmission scan was acquired using a 740
MBq 137Cs point source to correct for photon attenua-
tion. Subsequently, following injection of (R)-[11C]
PK11195, a dynamic emission scan with a total duration
of 90 minutes was acquired. All data were acquired in
64-bits list mode. After acquisition, list mode data were
converted into 16 sinograms with frame durations
increasing from 15 up to 300 s and reconstructed using
a three-dimensional ordered set expectation maximiza-
tion (OSEM 3-D) algorithm with a matrix size of 256 ×
256 × 207, resulting in a cubic voxel size of 1.21 × 1.21
× 1.21 mm3. Administered (R)-[11C]PK11195 activity
(15.8 ± 3.4 MBq/rat) and mass (0.15 ± 0.03 nmol/rat)
was not significantly different between TBI and control
rats.
Microdialysis
PET and glutamate measurements were conducted in
the same groups of animals. Immediately after CCI or
sham procedure, in all rats a 2 mm-length microdialysis
probe (CMA/12 14/02 PES CMA/Microdialysis, AB
Solna, Sweden) with an outer diameter of 0.5 mm and a
molecular weight cut-off of 100 kDa, was placed stereo-
tactically at a depth of 3 mm into the surrounding zone
of the lesion or normal brain parenchyma (controls)
according to the following coordinates: -1.5 mm from
bregma, 3.0 mm lateral from midsagittal line. The inlet
(12 cm) and outlet (7 cm) tubings from the microdialy-
sis probe were connected to a syringe cannula and a
microfraction collector, respectively. Exactly 5 minutes
after CCI or sham, perfusion of the semi-permeable sys-
tem with artificial cerebrospinal fluid was started at a
flow rate of 1.0 μl·min-1 (Figure 1). Five sequential dialy-
sate samples, at intervals of 60 minutes were collected
and analyzed for glutamate using a CMA 600 analyzer
(CMA/Microdialysis, Solna, Sweden).
Animals remained in the stereotactic frame through-
out the experiment. Vital signs were monitored continu-
ously and the level of anaesthesia was evaluated by
monitoring the pinch reflex every 15 minutes. Body
temperatures of the animals were kept within normal
range (37 -38 °C) using cooling and heating pads. At the
end of the experiment, the microdialysis probe was
removed, the scalp incision closed and the rat removed
from the stereotactic frame. After discontinuation of
anaesthesia, rats were extubated when breathing sponta-
neously and monitored until full recovery.
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Approval of the institutional animal ethics committee
was obtained and all experiments were carried out in
accordance with both the Dutch Law on Animal Experi-
mentation and guidelines of the institutional committee
on animal experimentation.
Brain tissue preparation
Ten days after the experiment, the entire brain was
removed promptly from the skull after decapitation. All
brains were fixed in 4% buffered formalin, processed
and embedded in paraffin according to routine proce-
dures. Fixed axial tissue sections of 8 μm were mounted
on coated slides and dried overnight at 37°C. Based on
routine HE staining of all sections throughout the brain,
selected slices of the lesion or sham region with an
extra margin of 2 mm around this area were selected
for (immuno)histochemical analysis.
(Immuno)histochemistry
Brain sections were immunohistochemically processed
using appropriate primary antibodies: ED1 (1:100;
mouse anti-rat lysosomal enzyme; Hycult Biotechnology,
Uden, The Netherlands), GFAP (anti Ga5 1:200, Biocon-
nect, Huissen. The Netherlands), or OX-6 (1:200; mouse
anti-rat MHC class II; AbD Serotec, Oxford, UK). After
ED1 and GFAP staining, the Envision kit detection
method (DAKO, Glostrup, DK) was used. For antibody
OX-6, the Streptavidin-Biotin-horseradish peroxidase
complex detection method was used (1:500, DAKO,
Glostrup, DK). Negative controls were included by
replacement of the primary antibodies with 1% bovine
serum albumin/phosphate-buffered saline. Finally, visua-
lization was performed using 0.02% 3.3’-diaminobenzi-
dine tetrahydrochloride. Subsequently, sections were
counterstained with haematoxylin, dehydrated and
mounted.
For histomorphological analysis of injury and inflam-
matory cells, routine haematoxylin and eosin (H&E)
staining was performed. Additionally, a routine Perl’s
iron staining was applied to identify the location of
posttraumatic haemorrhages. An anionic fluorochrome,
Fluoro-Jade B, was used as a marker for neuronal injury,
delineating both degenerating neuronal cell bodies and
its processes [14,15]. Briefly, after deparaffination and
dehydration, sections were rinsed in distilled H2O and
incubated at room temperature for 25 min in 0.06%
potassium permanganate to ensure background suppres-
sion. After washing in distilled H2O, sections were incu-
bated for another 30 min in a freshly prepared 0.001%
Fluoro-Jade B solution. Finally, sections were washed
thoroughly in distilled H2O, dried for one hour at 37 °C,
dipped in xylene and mounted.
A pathologist (AJR) and two investigators (JCFD;
CFMM) scored the ED-1, OX-6, Perl’s and Fluoro-Jade
B results. Scoring was divided into no, moderate and
strong positivity. In addition, the size of positive areas
was measured for ED-1 and OX-6. GFAP staining was
assessed for increased density of GFAP-positive astro-
cytes at the ipsilateral compared to the contralateral
side.
Image analysis
Time activity curves (TACs) of (R)-[11C]PK11195,
reflecting delivery of the tracer to the brain and binding
of the tracer to TSPO (right and left hemispheres), were
derived for predefined volume of interest (VOI), drawn
and copied from a standardized rat brain MRI, corrected
for injected dose and animal weight, using the software
package AMIDE (Amide 0.9.1 http://amide.sourceforge.
net). For every rat the injected dose was derived from a
VOI encompassing the total image. The TAC for this
VOI showed a maximum value in the initial frames,
after which a decrease was observed due to accumula-
tion into the bladder. The shape of various total image
TACs was similar, allowing a good estimate of the
injected dose from the maximum value of these curves.
Statistical Analysis
Statistical testing of areas under the curve (AUC)
between baseline TACs and TACs after TBI or sham
were performed using a one tailed Student’s t-test, test-
ing the a-priori hypothesis that (R)-[11C]PK11195 will be
increased after TBI. Microdialysis data are expressed as
mean ± standard deviation. Statistical significance of dif-
ferences in ECF glutamate between TBI rats and con-
trols at all time points was assessed using a one-tailed
Student’s t-test. Relationships between sham and TBI
for all stainings were calculated using Spearman’s corre-
lation statistics. Because of non-normal distribution and
differences in homogeneity of variances in protein
Figure 1 Microdialysis catheter inserted into the brain
parenchyma of an anaesthetized rat.
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expression levels (OX-6, ED-1, Perl’s and Fluoro-Jade B)
and lesion size (OX-6, ED-1 and Perl’s), as assessed by
the Kolmogorov-Smirnov test of normality and the
Levenes test, statistical evaluation was performed using
the non-parametric Mann-Whitney U test. P-values <
0.05 were considered statistically significant (SPSS ver-
sion 15.0.1, SPSS Inc., Chicago, IL, USA).
Results
(R)-[11C]PK11195 PET
In total, 28 PET scans were performed and 21 (R)-[11C]
PK11195 scans (9 baseline, 8 at day one (4 CCI, 4
sham), 4 at day 10 (2 CCI, 2 sham) were available for
further analysis. Two rats died after the baseline scan,
two rats died shortly after CCI and sham procedure due
to cardiac arrest, and another four rats died before day
ten. Representative examples of summed PET images of
baseline, one and ten days after TBI or sham procedure
are shown in Figure 2. One day after surgery, no statisti-
cally significant differences in (R)-[11C]PK11195 brain
uptake were found between TBI and control rats, nor
compared to baseline values. Ten days after TBI, how-
ever, an increase in cerebral uptake (SUV) of (R)-[11C]
PK11195 was statistically significant in TBI rats (0.79 ±
0.07) compared with both corresponding baseline values
(0.56 ± 0.05, p = 0.006) and sham-operated animals
(0.70 ± 0.06, p = 0.026) (Figure 3).
In vivo microdialysis
Accurate microdialysis samples were obtained for six
rats, three TBI and three sham (controls). In two rats,
sampling failed because of leakage of the microdialysis
probe. ECF glutamate values one hour after TBI were
significantly higher than corresponding values in sham
rats (27.6 ± 10.6 μmol·L-1 and 6.4 ± 3.6 μmol·L-1,
respectively; p < 0.05). Moreover, at all time points
mean glutamate levels in TBI rats were higher than in
sham controls (Figure 4).
Immunohistochemistry
Representative examples of brain tissue stained for ED-
1, OX-6, GFAP, Perl’s, and Fluoro-Jade B are shown in
Figure 5. The morphology of ED-1-positive cells clearly
indicates highly activated microglia and/or macrophages.
ED-1-positive cells were present in both TBI and sham-
operated rats, but the size of the area of positive ED-1
staining was larger in the ipsilateral hemisphere of TBI
rats, compared to both contralateral hemisphere and
sham-operated rats (Figure 5 A+B). OX-6 staining was
present predominantly in the ipsilateral hemisphere of
TBI rats. It was minimal in the contralateral hemisphere
and both hemispheres of sham-operated rats. OX-6-
positive cells were morphologically identified as acti-
vated microglia. The size of stained areas markedly dif-
fered between injured and non-injured brain tissue
(Figure 5 C+D). GFAP expression in the injured hemi-
sphere was increased compared with that in the contral-
ateral hemisphere. In sham-operated rats, the density of
astrocytes was homogeneous over the entire brain (Fig-
ure 5 E+F). Perl’s staining, indicative of haemorrhages,
was clearly increased in size and intensity in the injured
hemisphere of TBI rats (Figure 5 G+H). In TBI rats,
Fluoro Jade B positivity was exclusively seen in the ipsi-
lateral hemisphere of TBI rats (r = 0.83, p < 0.02). No
Figure 2 Representative examples of summed PET images showing uptake of (R)-[11C]PK11195 in rat brain at baseline and at one and
ten days after TBI or sham.
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Fluoro Jade B staining, indicating degenerating neurons
was found in the contralateral hemisphere nor in sham
brain tissue (Figure 5 I+J).
Discussion
This study demonstrates the technical feasibility of
TSPO imaging in experimental TBI. Correlations over
time were investigated between posttraumatic microglia
activation, determined by sequential (R)-[11C]PK11195
scans, ECF glutamate release, measured with in vivo cer-
ebral microdialysis, and (immuno)-histopathology in a
rat model of TBI. An increase was found in (R)-[11C]
PK11195 cerebral uptake ten days after TBI. Glutamate
concentrations were increased one hour after TBI com-
pared to those after sham procedure.
To acquire pharmacologically and physiologically
accurate ligand-receptor binding data in small animals
using HRRT, a high specific activity is required to main-
tain a low degree of receptor occupancy [16]. The
injected mass (0.15 ± 0.03 nmol/rat) in our study did
not exceed the limits of site occupancy and is consid-
ered to be a tracer dosage. The significant increase in
(R)-[11C]PK11195 uptake after TBI is in line with results
of Toyama et al. [17], who found increased (R)-[11C]
PK11195 binding in the injured site three days after an
Figure 3 Mean SUV of the image-derived injection dose (IDID)
with error bars over time for baseline (–), sham (О) and TBI (▴)
animals at 10 days.
Figure 4 Dialysate glutamate concentrations as a function of
time following CCI (♦ n = 3) and sham (о n = 3) (* p < 0.05).
Vertical lines represent SD. The arrow indicates baseline ECF
glutamate release (sham).
Figure 5 Representative images of (immuno)histochemical
staining of brain tissue (TBI and control) with ED-1, OX-6,
GFAP, Perl’s, and Fluoro-Jade B ten days after the microdialysis
experiment.
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ethanol brain injury. Ito et al. [18] found significant dif-
ferences in distribution volumes as well as an increased
expression of inflammatory cytokines between injured
and controls rats in specific brain areas four days after
injury. Recently, Yu et al. [19] found a more-than-3-fold
increase in [18F]fluoroethyl-DAA1106 uptake in trauma-
tized brain tissue compared to controls, peaking one
week after lateral fluid percussion brain injury. A rela-
tively rapid accumulation of phagocytic microglia and
macrophages at the necrotic core was reported, followed
by increased TSPO expression. Although ECF glutamate
was not measured, those findings are in line with the
present results.
Peak ECF glutamate concentrations were found in the
first hour of the microdialysis experiment. In TBI rats,
this peak concentration was significantly higher than in
controls. Over subsequent hours, glutamate concentra-
tions gradually declined in both groups, but remained
higher in TBI rats than in sham rats. When data from
cerebral microdialysis experiments are analysed, the
component resulting from the surgical procedure itself
has to be taken into account. By penetrating brain par-
enchyma, the microdialysis catheter could give rise to a
focal brain injury [20]. Haemostatic and local environ-
mental disturbances caused by this penetration might
result in temporary alterations in glutamate concentra-
tions in ECF. Woodroofe et al. [20] showed that, with-
out additional trauma, microdialysis catheters gave rise
to a local immune response in brain parenchyma two
days after implantation. Pathological excessive glutamate
release, exceeding excitotoxic thresholds, results in acti-
vation of postsynaptic ionotropic and metabotropic
receptors [21]. Activation of non-N-methyl-D-aspartate
(non-NMDA) glutamate receptors generates an influx of
monovalent cations (Na+ and K+) followed by a passive
influx of water, inducing cytotoxic oedema [22]. Activa-
tion of NMDA glutamate receptors elicit an excessive
influx of calcium, stimulating activation of phospholi-
pases and generation of oxygen-derived free radicals [2].
Taken together, this detrimental state of excitotoxicity
results in apoptosis of resident cells of the brain [23,24].
Consequently, NMDA antagonists may be beneficial in
preventing progressive brain injury after trauma [25].
Indeed, efficacy of NMDA antagonists has been demon-
strated in several preclinical brain injury studies. For
instance, NMDA antagonists may be beneficial in pre-
venting secondary neuronal damage by ischemia, neuro-
logical motor dysfunction, impairment in spatial
memory and focal brain edema at the site of injury.
Furthermore, they may affect synaptic plasticity [26-28].
In addition, in situ administration of kynurenic acid, an
EAA antagonist and specific NMDA receptor blocker,
attenuates rapid microglial and astroglial reactions in rat
hippocampus following TBI [29]. Results of the present
study underline that increased ECF glutamate concen-
trations in the acute posttraumatic phase precede
increased microglial activation in traumatized brain tis-
sue [30]. Future studies should address whether there is
a beneficial effect of EAA antagonists on late-phase
microglia activation.
Microglial activation and brain injury were assessed by
immunohistochemical and Fluoro Jade B staining. From
a morphological point of view, ED-1-positive cells are
activated macrophages and/or highly activated microglia.
The exclusive site where ED-1-positive cells were pre-
sent was at the ipsilateral hemisphere of TBI rats. This
is in accordance with a study by Lemstra et al. [31],
who showed that CD68 is a lysosomal membrane mar-
ker and predominantly stains microglia in a highly
active, phagocytic state. OX-6 is another suitable marker
of activated microglia, and OX-6 staining demonstrated
a clear difference between sham and TBI rats. The pre-
sent results indicate that both density and area of OX-6-
positive cells are higher at the site of injury. These find-
ings indicate that activated microglia have migrated to
the site of injury ten days after TBI which is in accor-
dance with studies by Cho et al [32]. In TBI, Fluoro-
Jade B is a very effective marker for locating degenerat-
ing neurons [14]. In the present study, Fluoro-Jade B-
positive cells were only seen in the injured hemisphere.
These findings, together with neuronal tissue damage
and microglia activation at the site of the injury confirm
increased (R)-[11C]PK11195 binding in the injured hemi-
sphere in TBI rats, ten days after CCI.
Conclusions
Significantly increased cerebral uptake of (R)-[11C]
PK11195 ten days after TBI points to prolonged and
ongoing activation of microglia. This increased posttrau-
matic microglia activation follows an acute posttrau-
matic ECF glutamate release.
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